Verastem's KRAS G12D vision; ADC Therapeutics reorganizes, lays off 17% of staff

Verastem eyes accelerated approval for KRAS G12D drug in 3 cancers; ADC Therapeutics cuts 17% of staff in restructuring.

Raccontata daendpoints.news